Israeli venture fund closes with $50 million:
This article was originally published in Clinica
Israeli venture capital fund Vitalife has just closed its first fund, worth $50m. Investors include Boston Scientific, HarbourVest Partners and Discount Capital Markets and Investments. Specialising in life sciences, Vitalife's portfolio consists of companies based in Israel or with links to Israel. They include MediGuide, which is developing electro-magnetic technology for guiding devices in the body, and SightLine, which specialises in video endoscopy for minimally invasive procedures.